Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
Sporadic Parkinson's disease (PD) constitutes 99% of the disorder, while the remaining 1% of the cases is of familial (genetic) origin. The mutations reported to be associated with familial PD indicate impairment in protein processing and misfolding, as is handled by the ubiquitin-proteasome system (UPS), and in mitochondrial function. For these reasons, we have recently applied, for the first time, Affymetrix oligonucleotide microarray technique in the substantia nigra pars compacta of sporadic parkinsonian patients for studying global gene expression analysis and comparison to the alterations identified in inherited PD. This study identified decreased expression of 68 genes and elevation of 69 genes. Classification into functional groups revealed that the downregulated genes are related to signal transduction, protein degradation (e.g., ubiquitin-proteasome subunits), dopaminergic transmission/metabolism, iron transport, protein modification/phosphorylation, and energy pathways/glycolysis functional classes. A major finding is the decreased expressions of 5 subunits of the UPS, SKP1A, a member of the SCF (E3) ubiquitin ligase complex, and chaperone HSC-70, which can lead to a wide impairment in the function of an entire repertoire of proteins. The upregulated genes are clustered in cell adhesion/cytoskeleton, extracellular matrix components, cell cycle, protein modification/phosphorylation, protein metabolism and transcription, and inflammation/hypoxia (e.g., key iron and oxygen sensor EGLN1) classes. The study shows, for the first time, a convergence in the pathogenic processes that are observed in hereditary (familial) and sporadic PD, where abnormal iron metabolism, oxidative stress, and aggregation of proteins occur. An additional breakthrough in this research is the identification of a number of previously unsuspected crucial gene players that are also involved in the process of neurodegeneration, which can serve as specific biomarkers for PD and novel drug development.
Mandel
Silvia
S
Eve Topf and USA National Parkinson Foundation Centers of Excellence and Department of Pharmacology, Family Research Institute, Technion-Rappaport Family Faculty of Medicine, Haifa, Israel.
Grunblatt
Edna
E
Riederer
Peter
P
Amariglio
Ninette
N
Jacob-Hirsch
Jasmine
J
Rechavi
Gideon
G
Youdim
Moussa B H
MB
D000444:Aldehyde Dehydrogenase / Q000378:metabolism*; D000818:Animals; D015815:Cell Adhesion Molecules / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism / Q000502:physiology; D020869:Gene Expression Profiling; D050883:HSC70 Heat-Shock Proteins / Q000378:metabolism*; D006801:Humans; D018384:Oxidative Stress / Q000502:physiology; D010300:Parkinson Disease / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D044786:S-Phase Kinase-Associated Proteins / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism*; D025801:Ubiquitin / Q000378:metabolism*
D015815:Cell Adhesion Molecules; D050883:HSC70 Heat-Shock Proteins; C494371:HSPA8 protein, human; D044786:S-Phase Kinase-Associated Proteins; D025801:Ubiquitin; D000444:Aldehyde Dehydrogenase; D046988:Proteasome Endopeptidase Complex; D004298:Dopamine